Exo Therapeutics
5 known investors
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
Founders & leadership
DL
David Liu, PhDFounder
AS
Alan Saghatelian, PhDCo-Founder
DL
David Liu
AS
Alan Saghetelian
Investors · 5
In the news
- Exo Therapeutics Raises $78M in Series B Financingfinsmes.com · 2021
- Exo Therapeutics adds $78M as cancer, inflammation drugs march toward clinic - MedCity Newsmedcitynews.com · 2021
- Novartis-backed Exo Therapeutics secures $78M to reprogram enzymes sans side effects | Fierce Biotechfiercebiotech.com · 2021
- Exo Therapeutics raises $78 million to target enzyme exosites with small moleculescen.acs.org · 2021
- Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites - BioSpacebiospace.com · 2020
- Exo Therapeutics snags $25M to handle 'undruggable' enzymes through their exosites | Fierce Biotechfiercebiotech.com · 2020